Mangoceuticals, Inc. (NASDAQ:MGRX) Financings

Mangoceuticals, Inc.

Financings

RaiseDate
Series D Cumulative Convertible Preferred Stock (tokenized)
Announced: up to US$10M · US$10 a share
Use of proceeds: General corporate purposes and working capital
Nov 12, 2026
Registered direct offering of units of one share of common stock and one warrant
Closed: US$500,000 raised · US$0.75 a unit · one warrant
Use of proceeds: Additional working capital
Oct 9, 2026
Strategic investment of membership interests in MangoRx IP Holdings, LLC
Tranche closed: US$1.75M raised
Use of proceeds: To advance commercialization of the antiviral intellectual property portfolio held by MangoRx IP
Oct 1, 2026
Registered direct offering of common Units (or Pre-Funded Units) of common stock and PIPE common warrants
Closed: US$2.5M raised · US$1.295 a unit · Warrants at US$1.4245 · Aegis Capital Corp.
Dealers: Aegis Capital Corp. (lead)
Use of proceeds: General corporate purposes and working capital
Dec 19, 2025

Read by 6ix AI from the company's releases